{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "e0a64cf2-4c25-4ad7-b851-e8c9daa56034",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Cell 1: Imports and environment checks\n",
    "\n",
    "import sqlite3\n",
    "import pandas as pd\n",
    "import os\n",
    "\n",
    "# (Optional) For printing DataFrames nicely in Jupyter:\n",
    "pd.set_option('display.max_columns', None)\n",
    "pd.set_option('display.max_colwidth', None)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "de23dce6-9557-429c-906f-6190cc991118",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Connected to database at /Users/yuxiangwang/Desktop/patents/data/patent.db\n"
     ]
    }
   ],
   "source": [
    "# Cell 2: Set up the database path and connect\n",
    "\n",
    "# Make sure this path is correct. If you're at your user home \"~\", you might need a full absolute path\n",
    "# For example: \"/Users/your_username/Desktop/patents/data/patent.db\"\n",
    "\n",
    "db_path = os.path.expanduser(\"~/Desktop/patents/data/patent.db\")\n",
    "\n",
    "# Connect to the SQLite database\n",
    "conn = sqlite3.connect(db_path)\n",
    "\n",
    "print(f\"Connected to database at {db_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "fade5c9a-0783-40d3-8e99-149c84b69d47",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>applications_claiming_priority</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>assignees</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>child_applications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>cited_by</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>claims</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>classifications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>concepts</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>error_logs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>events</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>external_links</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>images</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>inventors</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>legal_events</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>non_patent_citations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>parent_applications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>patent_citations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>patents</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>prior_art_keywords</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>priority_applications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>similar_documents</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>sqlite_sequence</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>worldwide_applications</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                              name\n",
       "0   applications_claiming_priority\n",
       "1                        assignees\n",
       "2               child_applications\n",
       "3                         cited_by\n",
       "4                           claims\n",
       "5                  classifications\n",
       "6                         concepts\n",
       "7                       error_logs\n",
       "8                           events\n",
       "9                   external_links\n",
       "10                          images\n",
       "11                       inventors\n",
       "12                    legal_events\n",
       "13            non_patent_citations\n",
       "14             parent_applications\n",
       "15                patent_citations\n",
       "16                         patents\n",
       "17              prior_art_keywords\n",
       "18           priority_applications\n",
       "19               similar_documents\n",
       "20                 sqlite_sequence\n",
       "21          worldwide_applications"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Cell 3: Explore more tables\n",
    "\n",
    "# Let's list out all the tables we have, by checking sqlite_master\n",
    "tables_query = \"\"\"\n",
    "SELECT name \n",
    "FROM sqlite_master \n",
    "WHERE type='table' \n",
    "ORDER BY name;\n",
    "\"\"\"\n",
    "df_tables = pd.read_sql(tables_query, conn)\n",
    "df_tables"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "1e59aaf6-e406-40f3-aa86-138f1d397244",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patent_id</th>\n",
       "      <th>title</th>\n",
       "      <th>type</th>\n",
       "      <th>pdf_link</th>\n",
       "      <th>publication_number</th>\n",
       "      <th>country</th>\n",
       "      <th>application_number</th>\n",
       "      <th>priority_date</th>\n",
       "      <th>filing_date</th>\n",
       "      <th>publication_date</th>\n",
       "      <th>prior_art_date</th>\n",
       "      <th>family_id</th>\n",
       "      <th>abstract</th>\n",
       "      <th>description_link</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>US20190160148A1</td>\n",
       "      <td>Combination of pembrolizumab and abemaciclib for the treatment of cancer</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/22/ef/4c/7eee828934d5ed/US20190160148A1.pdf</td>\n",
       "      <td>US20190160148A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US16/301,835</td>\n",
       "      <td>2016-05-23 00:00:00</td>\n",
       "      <td>2017-05-19 00:00:00</td>\n",
       "      <td>2019-05-30 00:00:00</td>\n",
       "      <td>2016-05-23 00:00:00</td>\n",
       "      <td>59021571</td>\n",
       "      <td>The present invention relates to a combination of abemaciclib and pembrolizumab and methods of using the combination to treat certain disorders, such as breast cancer and non-small cell lung cancer.</td>\n",
       "      <td>https://serpapi.com/searches/67cb376a460263e0dd05923f/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>US20210347889A1</td>\n",
       "      <td>Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/16/d4/e8/578718e90ac2cc/US20210347889A1.pdf</td>\n",
       "      <td>US20210347889A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US17/289,810</td>\n",
       "      <td>2018-11-05 00:00:00</td>\n",
       "      <td>2019-11-04 00:00:00</td>\n",
       "      <td>2021-11-11 00:00:00</td>\n",
       "      <td>2018-11-05 00:00:00</td>\n",
       "      <td>70611084</td>\n",
       "      <td>The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.</td>\n",
       "      <td>https://serpapi.com/searches/67cb376b39e4a8f068a55c1f/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>US20180333503A1</td>\n",
       "      <td>Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/62/ec/90/67d092982661c0/US20180333503A1.pdf</td>\n",
       "      <td>US20180333503A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US15/979,989</td>\n",
       "      <td>2017-05-16 00:00:00</td>\n",
       "      <td>2018-05-15 00:00:00</td>\n",
       "      <td>2018-11-22 00:00:00</td>\n",
       "      <td>2017-05-16 00:00:00</td>\n",
       "      <td>64269828</td>\n",
       "      <td>Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-PD-1 antibodies or antigen-binding fragments thereof (e.g., pembrolizumab) are provided. Methods of administering the combinations to treat cancers, e.g., ovarian, peritoneal, or fallopian tube cancers, with greater clinical efficacy and/or decreased toxicity are also provided.</td>\n",
       "      <td>https://serpapi.com/searches/67cb376cb7b03808798bfa8a/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>US20210403557A1</td>\n",
       "      <td>Dosing regimen of anti-tigit antibody for treatment of cancer</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/af/00/bb/a9e1b627545c6a/US20210403557A1.pdf</td>\n",
       "      <td>US20210403557A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US17/288,641</td>\n",
       "      <td>2018-11-05 00:00:00</td>\n",
       "      <td>2019-11-04 00:00:00</td>\n",
       "      <td>2021-12-30 00:00:00</td>\n",
       "      <td>2018-11-05 00:00:00</td>\n",
       "      <td>70611082</td>\n",
       "      <td>The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.</td>\n",
       "      <td>https://serpapi.com/searches/67cb376ebc84b8472472ff5b/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>US20170089914A1</td>\n",
       "      <td>Anti-pembrolizumab antibodies</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/8c/6b/a3/cfa14432c1dc01/US20170089914A1.pdf</td>\n",
       "      <td>US20170089914A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US15/274,330</td>\n",
       "      <td>2015-09-25 00:00:00</td>\n",
       "      <td>2016-09-23 00:00:00</td>\n",
       "      <td>2017-03-30 00:00:00</td>\n",
       "      <td>2015-09-25 00:00:00</td>\n",
       "      <td>58408842</td>\n",
       "      <td>The present invention provides antibodies and antigen-binding fragments thereof that bind to the antibody pembrolizumab (pembrolizumab). These antibodies are useful, for example, for use as positive controls in assays for detecting the presence of anti-drug antibodies in a sample, e.g., the blood of a patient who has been administered pembrolizumab.</td>\n",
       "      <td>https://serpapi.com/searches/67cb37703dca69e505f1441d/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>US20200361931A1</td>\n",
       "      <td>Prmt5 inhibitors</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/1b/c1/9e/f29a0a5b8413f6/US20200361931A1.pdf</td>\n",
       "      <td>US20200361931A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US16/762,201</td>\n",
       "      <td>2017-11-08 00:00:00</td>\n",
       "      <td>2018-11-05 00:00:00</td>\n",
       "      <td>2020-11-19 00:00:00</td>\n",
       "      <td>2017-11-08 00:00:00</td>\n",
       "      <td>66438946</td>\n",
       "      <td>The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.</td>\n",
       "      <td>https://serpapi.com/searches/67cb37e656f17df444dbeca3/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>US20190241655A1</td>\n",
       "      <td>Ilt3 ligand</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/50/bf/c2/1e4cdc39a6b193/US20190241655A1.pdf</td>\n",
       "      <td>US20190241655A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US16/342,582</td>\n",
       "      <td>2016-11-10 00:00:00</td>\n",
       "      <td>2017-11-06 00:00:00</td>\n",
       "      <td>2019-08-08 00:00:00</td>\n",
       "      <td>2016-11-10 00:00:00</td>\n",
       "      <td>62109704</td>\n",
       "      <td>The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.</td>\n",
       "      <td>https://serpapi.com/searches/67cb37e9e8a9fadbfc854d66/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>US20220267369A1</td>\n",
       "      <td>Methods of separating host cell lipases from a production protein in chromatographic processes</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/e9/fb/b2/19e87f2fec41dc/US20220267369A1.pdf</td>\n",
       "      <td>US20220267369A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US17/261,365</td>\n",
       "      <td>2018-07-25 00:00:00</td>\n",
       "      <td>2019-07-24 00:00:00</td>\n",
       "      <td>2022-08-25 00:00:00</td>\n",
       "      <td>2018-07-25 00:00:00</td>\n",
       "      <td>69180557</td>\n",
       "      <td>Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from the production protein using chromatographic processes. Also provided are pharmaceutical compositions comprising less than 1 ppm of a host cell lipase.</td>\n",
       "      <td>https://serpapi.com/searches/67cb37eb4ef4fde4be2d9fcb/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>US20200048258A1</td>\n",
       "      <td>Kdm5 inhibitors</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/a9/78/25/da053ed4a2005f/US20200048258A1.pdf</td>\n",
       "      <td>US20200048258A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US16/341,313</td>\n",
       "      <td>2016-10-12 00:00:00</td>\n",
       "      <td>2017-10-06 00:00:00</td>\n",
       "      <td>2020-02-13 00:00:00</td>\n",
       "      <td>2016-10-12 00:00:00</td>\n",
       "      <td>61905936</td>\n",
       "      <td>The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.</td>\n",
       "      <td>https://serpapi.com/searches/67cb37eda0fdbcf7aa5ba4a8/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>US20210214308A1</td>\n",
       "      <td>Novel [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors</td>\n",
       "      <td>patent</td>\n",
       "      <td>https://patentimages.storage.googleapis.com/3b/3c/e3/f1a9f582ddcaaf/US20210214308A1.pdf</td>\n",
       "      <td>US20210214308A1</td>\n",
       "      <td>United States</td>\n",
       "      <td>US17/057,959</td>\n",
       "      <td>2018-06-01 00:00:00</td>\n",
       "      <td>2019-05-28 00:00:00</td>\n",
       "      <td>2021-07-15 00:00:00</td>\n",
       "      <td>2018-06-01 00:00:00</td>\n",
       "      <td>68698979</td>\n",
       "      <td>Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an DO-associated disease or disorder.</td>\n",
       "      <td>https://serpapi.com/searches/67cb37f11b26bcf3f9927cb5/google_patents_details/description.html</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>66 rows × 14 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          patent_id  \\\n",
       "0   US20190160148A1   \n",
       "1   US20210347889A1   \n",
       "2   US20180333503A1   \n",
       "3   US20210403557A1   \n",
       "4   US20170089914A1   \n",
       "..              ...   \n",
       "61  US20200361931A1   \n",
       "62  US20190241655A1   \n",
       "63  US20220267369A1   \n",
       "64  US20200048258A1   \n",
       "65  US20210214308A1   \n",
       "\n",
       "                                                                                                       title  \\\n",
       "0                                   Combination of pembrolizumab and abemaciclib for the treatment of cancer   \n",
       "1   Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer   \n",
       "2                                            Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations   \n",
       "3                                              Dosing regimen of anti-tigit antibody for treatment of cancer   \n",
       "4                                                                              Anti-pembrolizumab antibodies   \n",
       "..                                                                                                       ...   \n",
       "61                                                                                          Prmt5 inhibitors   \n",
       "62                                                                                               Ilt3 ligand   \n",
       "63            Methods of separating host cell lipases from a production protein in chromatographic processes   \n",
       "64                                                                                           Kdm5 inhibitors   \n",
       "65                                 Novel [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors   \n",
       "\n",
       "      type  \\\n",
       "0   patent   \n",
       "1   patent   \n",
       "2   patent   \n",
       "3   patent   \n",
       "4   patent   \n",
       "..     ...   \n",
       "61  patent   \n",
       "62  patent   \n",
       "63  patent   \n",
       "64  patent   \n",
       "65  patent   \n",
       "\n",
       "                                                                                   pdf_link  \\\n",
       "0   https://patentimages.storage.googleapis.com/22/ef/4c/7eee828934d5ed/US20190160148A1.pdf   \n",
       "1   https://patentimages.storage.googleapis.com/16/d4/e8/578718e90ac2cc/US20210347889A1.pdf   \n",
       "2   https://patentimages.storage.googleapis.com/62/ec/90/67d092982661c0/US20180333503A1.pdf   \n",
       "3   https://patentimages.storage.googleapis.com/af/00/bb/a9e1b627545c6a/US20210403557A1.pdf   \n",
       "4   https://patentimages.storage.googleapis.com/8c/6b/a3/cfa14432c1dc01/US20170089914A1.pdf   \n",
       "..                                                                                      ...   \n",
       "61  https://patentimages.storage.googleapis.com/1b/c1/9e/f29a0a5b8413f6/US20200361931A1.pdf   \n",
       "62  https://patentimages.storage.googleapis.com/50/bf/c2/1e4cdc39a6b193/US20190241655A1.pdf   \n",
       "63  https://patentimages.storage.googleapis.com/e9/fb/b2/19e87f2fec41dc/US20220267369A1.pdf   \n",
       "64  https://patentimages.storage.googleapis.com/a9/78/25/da053ed4a2005f/US20200048258A1.pdf   \n",
       "65  https://patentimages.storage.googleapis.com/3b/3c/e3/f1a9f582ddcaaf/US20210214308A1.pdf   \n",
       "\n",
       "   publication_number        country application_number        priority_date  \\\n",
       "0     US20190160148A1  United States       US16/301,835  2016-05-23 00:00:00   \n",
       "1     US20210347889A1  United States       US17/289,810  2018-11-05 00:00:00   \n",
       "2     US20180333503A1  United States       US15/979,989  2017-05-16 00:00:00   \n",
       "3     US20210403557A1  United States       US17/288,641  2018-11-05 00:00:00   \n",
       "4     US20170089914A1  United States       US15/274,330  2015-09-25 00:00:00   \n",
       "..                ...            ...                ...                  ...   \n",
       "61    US20200361931A1  United States       US16/762,201  2017-11-08 00:00:00   \n",
       "62    US20190241655A1  United States       US16/342,582  2016-11-10 00:00:00   \n",
       "63    US20220267369A1  United States       US17/261,365  2018-07-25 00:00:00   \n",
       "64    US20200048258A1  United States       US16/341,313  2016-10-12 00:00:00   \n",
       "65    US20210214308A1  United States       US17/057,959  2018-06-01 00:00:00   \n",
       "\n",
       "            filing_date     publication_date       prior_art_date family_id  \\\n",
       "0   2017-05-19 00:00:00  2019-05-30 00:00:00  2016-05-23 00:00:00  59021571   \n",
       "1   2019-11-04 00:00:00  2021-11-11 00:00:00  2018-11-05 00:00:00  70611084   \n",
       "2   2018-05-15 00:00:00  2018-11-22 00:00:00  2017-05-16 00:00:00  64269828   \n",
       "3   2019-11-04 00:00:00  2021-12-30 00:00:00  2018-11-05 00:00:00  70611082   \n",
       "4   2016-09-23 00:00:00  2017-03-30 00:00:00  2015-09-25 00:00:00  58408842   \n",
       "..                  ...                  ...                  ...       ...   \n",
       "61  2018-11-05 00:00:00  2020-11-19 00:00:00  2017-11-08 00:00:00  66438946   \n",
       "62  2017-11-06 00:00:00  2019-08-08 00:00:00  2016-11-10 00:00:00  62109704   \n",
       "63  2019-07-24 00:00:00  2022-08-25 00:00:00  2018-07-25 00:00:00  69180557   \n",
       "64  2017-10-06 00:00:00  2020-02-13 00:00:00  2016-10-12 00:00:00  61905936   \n",
       "65  2019-05-28 00:00:00  2021-07-15 00:00:00  2018-06-01 00:00:00  68698979   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  abstract  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                   The present invention relates to a combination of abemaciclib and pembrolizumab and methods of using the combination to treat certain disorders, such as breast cancer and non-small cell lung cancer.   \n",
       "1   The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.   \n",
       "2                                                                                                                                                                                                                                                                                         Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-PD-1 antibodies or antigen-binding fragments thereof (e.g., pembrolizumab) are provided. Methods of administering the combinations to treat cancers, e.g., ovarian, peritoneal, or fallopian tube cancers, with greater clinical efficacy and/or decreased toxicity are also provided.   \n",
       "3                                                                                                                                                                                                                                                                                                                     The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.   \n",
       "4                                                                                                                                                                                                                                                                                                          The present invention provides antibodies and antigen-binding fragments thereof that bind to the antibody pembrolizumab (pembrolizumab). These antibodies are useful, for example, for use as positive controls in assays for detecting the presence of anti-drug antibodies in a sample, e.g., the blood of a patient who has been administered pembrolizumab.   \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ...   \n",
       "61                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.   \n",
       "62                                                                                                                                                                                                                                                                                                                                           The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.   \n",
       "63                                                                                                                                                                                                                                                                   Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from the production protein using chromatographic processes. Also provided are pharmaceutical compositions comprising less than 1 ppm of a host cell lipase.   \n",
       "64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.   \n",
       "65                                                                                                                                                                                                                                 Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an DO-associated disease or disorder.   \n",
       "\n",
       "                                                                                 description_link  \n",
       "0   https://serpapi.com/searches/67cb376a460263e0dd05923f/google_patents_details/description.html  \n",
       "1   https://serpapi.com/searches/67cb376b39e4a8f068a55c1f/google_patents_details/description.html  \n",
       "2   https://serpapi.com/searches/67cb376cb7b03808798bfa8a/google_patents_details/description.html  \n",
       "3   https://serpapi.com/searches/67cb376ebc84b8472472ff5b/google_patents_details/description.html  \n",
       "4   https://serpapi.com/searches/67cb37703dca69e505f1441d/google_patents_details/description.html  \n",
       "..                                                                                            ...  \n",
       "61  https://serpapi.com/searches/67cb37e656f17df444dbeca3/google_patents_details/description.html  \n",
       "62  https://serpapi.com/searches/67cb37e9e8a9fadbfc854d66/google_patents_details/description.html  \n",
       "63  https://serpapi.com/searches/67cb37eb4ef4fde4be2d9fcb/google_patents_details/description.html  \n",
       "64  https://serpapi.com/searches/67cb37eda0fdbcf7aa5ba4a8/google_patents_details/description.html  \n",
       "65  https://serpapi.com/searches/67cb37f11b26bcf3f9927cb5/google_patents_details/description.html  \n",
       "\n",
       "[66 rows x 14 columns]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Cell 4: Quick look at the main 'patents' table\n",
    "\n",
    "query = \"SELECT * FROM patents\"\n",
    "df_patents = pd.read_sql(query, conn)\n",
    "df_patents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6f5a6f40-81ec-4998-8fd4-b002ffa045e2",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5c06c3fe-1aad-4384-b19e-eb6d5da8cff8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "d96d4474-d55f-4c40-9609-ca31751c779a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>patent_id</th>\n",
       "      <th>claim_no</th>\n",
       "      <th>claim_txt</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>US20190160148A1</td>\n",
       "      <td>1</td>\n",
       "      <td>1. A method of treating breast cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6, CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 on day 1 of a 21-day cycle and 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof twice daily on days 1-21 of the 21-day cycle.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>US20190160148A1</td>\n",
       "      <td>2</td>\n",
       "      <td>2. A method of treating breast cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6 , CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 in combination with 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof wherein initial administration of the abemaciclib or the salt thereof is administered to the patient without the antibody or the antigen binding fragment thereof for at least 24 hours and the abemaciclib or the salt thereof is then administered to the patient in combination with the antibody or the antigen binding fragment thereof.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>US20190160148A1</td>\n",
       "      <td>3</td>\n",
       "      <td>3. The method according to claim 1, wherein the antibody or antigen binding fragment thereof comprises a light chain variable region (LCVR) amino acid sequence of SEQ ID NO:1 and a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 2.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>US20190160148A1</td>\n",
       "      <td>4</td>\n",
       "      <td>4. (canceled)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>US20190160148A1</td>\n",
       "      <td>5</td>\n",
       "      <td>5. (canceled)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2165</th>\n",
       "      <td>2166</td>\n",
       "      <td>US20220380469A1</td>\n",
       "      <td>12</td>\n",
       "      <td>12. The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered to the patient by intravenous or subcutaneous administration.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2166</th>\n",
       "      <td>2167</td>\n",
       "      <td>US20220380469A1</td>\n",
       "      <td>13</td>\n",
       "      <td>13. The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is pembrolizumab.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2167</th>\n",
       "      <td>2168</td>\n",
       "      <td>US20220380469A1</td>\n",
       "      <td>14</td>\n",
       "      <td>14. The method of claim 1, wherein the method comprises administering:\\n(i) about 200 mg of an anti-PD-1 antibody, or antigen binding fragment thereof, to the patient every approximately three weeks; or (ii) about 400 mg of an anti-PD-1 antibody, or antigen binding fragment thereof, to the patient every approximately six weeks.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2168</th>\n",
       "      <td>2169</td>\n",
       "      <td>US20220380469A1</td>\n",
       "      <td>15</td>\n",
       "      <td>15. The method of claim 8, wherein the patient has disease progression following the at least two prior systemic treatments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2169</th>\n",
       "      <td>2170</td>\n",
       "      <td>US20220380469A1</td>\n",
       "      <td>16</td>\n",
       "      <td>16. The method of claim 8, wherein the at least two prior systemic treatments comprise treatment with an anthracycline and/or a taxane in the neoadjuvant, adjuvant, or metastatic setting.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2170 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        id        patent_id  claim_no  \\\n",
       "0        1  US20190160148A1         1   \n",
       "1        2  US20190160148A1         2   \n",
       "2        3  US20190160148A1         3   \n",
       "3        4  US20190160148A1         4   \n",
       "4        5  US20190160148A1         5   \n",
       "...    ...              ...       ...   \n",
       "2165  2166  US20220380469A1        12   \n",
       "2166  2167  US20220380469A1        13   \n",
       "2167  2168  US20220380469A1        14   \n",
       "2168  2169  US20220380469A1        15   \n",
       "2169  2170  US20220380469A1        16   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             claim_txt  \n",
       "0                                                                                                                                                                                                                                                                                           1. A method of treating breast cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6, CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 on day 1 of a 21-day cycle and 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof twice daily on days 1-21 of the 21-day cycle.  \n",
       "1     2. A method of treating breast cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6 , CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 in combination with 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof wherein initial administration of the abemaciclib or the salt thereof is administered to the patient without the antibody or the antigen binding fragment thereof for at least 24 hours and the abemaciclib or the salt thereof is then administered to the patient in combination with the antibody or the antigen binding fragment thereof.  \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3. The method according to claim 1, wherein the antibody or antigen binding fragment thereof comprises a light chain variable region (LCVR) amino acid sequence of SEQ ID NO:1 and a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 2.  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        4. (canceled)  \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        5. (canceled)  \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...  \n",
       "2165                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       12. The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered to the patient by intravenous or subcutaneous administration.  \n",
       "2166                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   13. The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is pembrolizumab.  \n",
       "2167                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         14. The method of claim 1, wherein the method comprises administering:\\n(i) about 200 mg of an anti-PD-1 antibody, or antigen binding fragment thereof, to the patient every approximately three weeks; or (ii) about 400 mg of an anti-PD-1 antibody, or antigen binding fragment thereof, to the patient every approximately six weeks.  \n",
       "2168                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      15. The method of claim 8, wherein the patient has disease progression following the at least two prior systemic treatments.  \n",
       "2169                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       16. The method of claim 8, wherein the at least two prior systemic treatments comprise treatment with an anthracycline and/or a taxane in the neoadjuvant, adjuvant, or metastatic setting.  \n",
       "\n",
       "[2170 rows x 4 columns]"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query = \"SELECT * FROM claims\"\n",
    "df_patents = pd.read_sql(query, conn)\n",
    "df_patents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "06b7c964-3a0b-4ab6-96b1-e49efcba2241",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "df3b0803-75c5-43ac-b623-540f8bde5b72",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "706c52f4-e465-4b35-bd97-eca8fe305039",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "89ef9901-9fec-44b1-80df-f2e760ac1484",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3.12 (patent)",
   "language": "python",
   "name": "patent"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
